vTv Therapeutics
VTVT
vTv Therapeutics (VTVT) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.92
- EPS estimate
- −$0.83
- EPS surprise
- −11.52%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 12, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 12, 2025 | −$0.83 | −$0.92 | −11.52% | $0.00 | SEC |
| Q1 2025 | May 15, 2025 | −$0.82 | −$0.77 | +5.52% | $0.00 | SEC |
| Q4 2024 | Mar 20, 2025 | −$0.87 | −$0.55 | +36.78% | $17,000.00 | SEC |
| Q3 2024 | Nov 12, 2024 | −$3.60 | −$0.88 | +75.56% | $0.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$3.20 | −$0.81 | +74.69% | $0.00 | SEC |
| Q1 2024 | May 9, 2024 | −$3.20 | −$1.17 | +63.44% | $1.0M | SEC |
| Q4 2023 | Mar 13, 2024 | −$2.80 | −$1.67 | +40.36% | $0.00 | SEC |
| Q3 2023 | Nov 9, 2023 | −$3.20 | −$3.20 | +0.00% | $0.00 | SEC |
| Q2 2023 | Aug 11, 2023 | −$2.80 | −$2.80 | +0.00% | $0.00 | SEC |
| Q1 2023 | May 11, 2023 | −$3.80 | −$2.40 | +36.84% | $0.00 | SEC |
| Q4 2022 | Mar 6, 2023 | −$2.53 | −$2.40 | +5.26% | $9,000.00 | SEC |
| Q3 2022 | Nov 10, 2022 | −$1.73 | −$2.00 | −15.39% | $0.00 | — |
| Q2 2022 | Aug 15, 2022 | −$3.60 | −$1.60 | +55.56% | $9,000.00 | SEC |
| Q1 2022 | May 12, 2022 | −$2.80 | −$4.00 | −42.86% | $2.0M | SEC |
| Q4 2021 | Mar 29, 2022 | −$2.53 | −$3.20 | −26.32% | $9,000.00 | SEC |
| Q3 2021 | Nov 9, 2021 | −$2.60 | −$0.80 | +69.23% | $3.0M | SEC |
| Q2 2021 | Aug 4, 2021 | −$2.80 | −$0.40 | +85.71% | $9,000.00 | SEC |
| Q1 2021 | May 5, 2021 | −$2.40 | −$3.20 | −33.33% | $987,000.00 | SEC |
| Q4 2020 | Feb 24, 2021 | −$2.20 | $0.80 | +136.36% | $6.4M | SEC |
| Q3 2020 | Nov 5, 2020 | −$4.20 | −$0.80 | +80.95% | $7,000.00 | SEC |
Quarterly revenue
Frequently asked questions
When did vTv Therapeutics (VTVT) last report earnings?
vTv Therapeutics last reported on Aug 12, 2025, covering fiscal Q2 2025.
Did VTVT beat earnings estimates?
No. vTv Therapeutics reported EPS of −$0.92 for Q2 2025 against a −$0.83 estimate — a 11.52% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.